Responses
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results
Compose a Response to This Article
Other responses
No responses have been published for this article.